Ranitidine-induced anaphylaxis: Clinical features, cross-reactivity, and skin testing

K. H. Park, J. Pai, D. G. Song, D. W. Sim, H. J. Park, J. H. Lee, K. Y. Jeong, C. H. Pan, I. Shin, Jungwon Park

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Summary: Background: Histamine H2 receptor antagonists are commonly prescribed medications and are known to be well tolerated. However, 99 cases of ranitidine-induced anaphylaxis occurred in Korea from 2007 to 2014. Objective: The purpose of this study was to determine the incidence, clinical features, and diagnostic methods for ranitidine-induced anaphylaxis. Methods: Ranitidine-related pharmacovigilance data from 2007 to 2014 were reviewed. Adverse drug reactions with causal relationships were selected, and clinical manifestations, outcomes, and drug-related information were assessed. For further investigation, 8 years of pharmacovigilance data were collected at a single centre. Twenty-three patients participated in in vivo and in vitro studies. Skin tests, oral provocation tests, and laboratory tests were performed, including tests using other kinds of histamine H2 receptor antagonists. Results: Over 7 years, 584 patients suffered adverse reactions to ranitidine. The most common manifestation was cutaneous symptoms. Among them, 99 patients (17.0%) experienced anaphylaxis. In a single-centre study, skin prick tests were positive in 91.7% of ranitidine-induced anaphylaxis patients (11/12); the optimal concentration was 20 mg/mL. Detection of ranitidine-specific immunoglobulin E failed. Cimetidine and proton pump inhibitors showed no cross-reactivity with ranitidine based on the skin prick test, oral provocation test, or clinical determination. Surprisingly, 82.6% of patients reintroduced ranitidine and re-experienced the same adverse reactions because ranitidine was not considered the culprit drug. Conclusions and Clinical Relevance: Although ranitidine is known as a safe drug, it can also cause diverse adverse reactions, including anaphylaxis. This study demonstrates the need to pay attention to adverse reactions to ranitidine and consider ranitidine as a cause of anaphylaxis.

Original languageEnglish
Pages (from-to)631-639
Number of pages9
JournalClinical and Experimental Allergy
Volume46
Issue number4
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

Ranitidine
Anaphylaxis
Skin
Skin Tests
Histamine H2 Antagonists
Pharmacovigilance
Pharmaceutical Preparations
Proton Pump Inhibitors
Cimetidine
Korea
Drug-Related Side Effects and Adverse Reactions
Immunoglobulin E

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Park, K. H. ; Pai, J. ; Song, D. G. ; Sim, D. W. ; Park, H. J. ; Lee, J. H. ; Jeong, K. Y. ; Pan, C. H. ; Shin, I. ; Park, Jungwon. / Ranitidine-induced anaphylaxis : Clinical features, cross-reactivity, and skin testing. In: Clinical and Experimental Allergy. 2016 ; Vol. 46, No. 4. pp. 631-639.
@article{d962f4bba91f43368624015e3b8b8413,
title = "Ranitidine-induced anaphylaxis: Clinical features, cross-reactivity, and skin testing",
abstract = "Summary: Background: Histamine H2 receptor antagonists are commonly prescribed medications and are known to be well tolerated. However, 99 cases of ranitidine-induced anaphylaxis occurred in Korea from 2007 to 2014. Objective: The purpose of this study was to determine the incidence, clinical features, and diagnostic methods for ranitidine-induced anaphylaxis. Methods: Ranitidine-related pharmacovigilance data from 2007 to 2014 were reviewed. Adverse drug reactions with causal relationships were selected, and clinical manifestations, outcomes, and drug-related information were assessed. For further investigation, 8 years of pharmacovigilance data were collected at a single centre. Twenty-three patients participated in in vivo and in vitro studies. Skin tests, oral provocation tests, and laboratory tests were performed, including tests using other kinds of histamine H2 receptor antagonists. Results: Over 7 years, 584 patients suffered adverse reactions to ranitidine. The most common manifestation was cutaneous symptoms. Among them, 99 patients (17.0{\%}) experienced anaphylaxis. In a single-centre study, skin prick tests were positive in 91.7{\%} of ranitidine-induced anaphylaxis patients (11/12); the optimal concentration was 20 mg/mL. Detection of ranitidine-specific immunoglobulin E failed. Cimetidine and proton pump inhibitors showed no cross-reactivity with ranitidine based on the skin prick test, oral provocation test, or clinical determination. Surprisingly, 82.6{\%} of patients reintroduced ranitidine and re-experienced the same adverse reactions because ranitidine was not considered the culprit drug. Conclusions and Clinical Relevance: Although ranitidine is known as a safe drug, it can also cause diverse adverse reactions, including anaphylaxis. This study demonstrates the need to pay attention to adverse reactions to ranitidine and consider ranitidine as a cause of anaphylaxis.",
author = "Park, {K. H.} and J. Pai and Song, {D. G.} and Sim, {D. W.} and Park, {H. J.} and Lee, {J. H.} and Jeong, {K. Y.} and Pan, {C. H.} and I. Shin and Jungwon Park",
year = "2016",
month = "4",
day = "1",
doi = "10.1111/cea.12708",
language = "English",
volume = "46",
pages = "631--639",
journal = "Clinical and Experimental Allergy",
issn = "0954-7894",
publisher = "Wiley-Blackwell",
number = "4",

}

Park, KH, Pai, J, Song, DG, Sim, DW, Park, HJ, Lee, JH, Jeong, KY, Pan, CH, Shin, I & Park, J 2016, 'Ranitidine-induced anaphylaxis: Clinical features, cross-reactivity, and skin testing', Clinical and Experimental Allergy, vol. 46, no. 4, pp. 631-639. https://doi.org/10.1111/cea.12708

Ranitidine-induced anaphylaxis : Clinical features, cross-reactivity, and skin testing. / Park, K. H.; Pai, J.; Song, D. G.; Sim, D. W.; Park, H. J.; Lee, J. H.; Jeong, K. Y.; Pan, C. H.; Shin, I.; Park, Jungwon.

In: Clinical and Experimental Allergy, Vol. 46, No. 4, 01.04.2016, p. 631-639.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Ranitidine-induced anaphylaxis

T2 - Clinical features, cross-reactivity, and skin testing

AU - Park, K. H.

AU - Pai, J.

AU - Song, D. G.

AU - Sim, D. W.

AU - Park, H. J.

AU - Lee, J. H.

AU - Jeong, K. Y.

AU - Pan, C. H.

AU - Shin, I.

AU - Park, Jungwon

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Summary: Background: Histamine H2 receptor antagonists are commonly prescribed medications and are known to be well tolerated. However, 99 cases of ranitidine-induced anaphylaxis occurred in Korea from 2007 to 2014. Objective: The purpose of this study was to determine the incidence, clinical features, and diagnostic methods for ranitidine-induced anaphylaxis. Methods: Ranitidine-related pharmacovigilance data from 2007 to 2014 were reviewed. Adverse drug reactions with causal relationships were selected, and clinical manifestations, outcomes, and drug-related information were assessed. For further investigation, 8 years of pharmacovigilance data were collected at a single centre. Twenty-three patients participated in in vivo and in vitro studies. Skin tests, oral provocation tests, and laboratory tests were performed, including tests using other kinds of histamine H2 receptor antagonists. Results: Over 7 years, 584 patients suffered adverse reactions to ranitidine. The most common manifestation was cutaneous symptoms. Among them, 99 patients (17.0%) experienced anaphylaxis. In a single-centre study, skin prick tests were positive in 91.7% of ranitidine-induced anaphylaxis patients (11/12); the optimal concentration was 20 mg/mL. Detection of ranitidine-specific immunoglobulin E failed. Cimetidine and proton pump inhibitors showed no cross-reactivity with ranitidine based on the skin prick test, oral provocation test, or clinical determination. Surprisingly, 82.6% of patients reintroduced ranitidine and re-experienced the same adverse reactions because ranitidine was not considered the culprit drug. Conclusions and Clinical Relevance: Although ranitidine is known as a safe drug, it can also cause diverse adverse reactions, including anaphylaxis. This study demonstrates the need to pay attention to adverse reactions to ranitidine and consider ranitidine as a cause of anaphylaxis.

AB - Summary: Background: Histamine H2 receptor antagonists are commonly prescribed medications and are known to be well tolerated. However, 99 cases of ranitidine-induced anaphylaxis occurred in Korea from 2007 to 2014. Objective: The purpose of this study was to determine the incidence, clinical features, and diagnostic methods for ranitidine-induced anaphylaxis. Methods: Ranitidine-related pharmacovigilance data from 2007 to 2014 were reviewed. Adverse drug reactions with causal relationships were selected, and clinical manifestations, outcomes, and drug-related information were assessed. For further investigation, 8 years of pharmacovigilance data were collected at a single centre. Twenty-three patients participated in in vivo and in vitro studies. Skin tests, oral provocation tests, and laboratory tests were performed, including tests using other kinds of histamine H2 receptor antagonists. Results: Over 7 years, 584 patients suffered adverse reactions to ranitidine. The most common manifestation was cutaneous symptoms. Among them, 99 patients (17.0%) experienced anaphylaxis. In a single-centre study, skin prick tests were positive in 91.7% of ranitidine-induced anaphylaxis patients (11/12); the optimal concentration was 20 mg/mL. Detection of ranitidine-specific immunoglobulin E failed. Cimetidine and proton pump inhibitors showed no cross-reactivity with ranitidine based on the skin prick test, oral provocation test, or clinical determination. Surprisingly, 82.6% of patients reintroduced ranitidine and re-experienced the same adverse reactions because ranitidine was not considered the culprit drug. Conclusions and Clinical Relevance: Although ranitidine is known as a safe drug, it can also cause diverse adverse reactions, including anaphylaxis. This study demonstrates the need to pay attention to adverse reactions to ranitidine and consider ranitidine as a cause of anaphylaxis.

UR - http://www.scopus.com/inward/record.url?scp=84961662029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961662029&partnerID=8YFLogxK

U2 - 10.1111/cea.12708

DO - 10.1111/cea.12708

M3 - Article

C2 - 26764898

AN - SCOPUS:84961662029

VL - 46

SP - 631

EP - 639

JO - Clinical and Experimental Allergy

JF - Clinical and Experimental Allergy

SN - 0954-7894

IS - 4

ER -